AssetID: 53225739
Headline: FDA Expert Panel to Determine the Efficacy of Merck's Chronic Cough Medication
Caption: On November 15, health regulators in the United States flagged concerns that Merck's chronic cough drug, gefapixant, may not have a meaningful benefit. Reuters reports that the concerns were listed in documents released ahead of a meeting of independent experts.
Keywords: FDA,expert,panel,determine,efficacy,Merck,Chronic,cough,medication,gefapixant,meaningful,works,effective,health,brand,Lyfnua,stimulate,nerves,trigger,condition,block,receptors
PersonInImage: